An initiative from the Veterans Health Administration to reduce methicillin resistant Staphylococcus aureus (MRSA) and other healthcare-associated infections in the facilities has led to marked infection reduction around the country.
University of Connecticut researchers have developed novel antibiotic compounds to target methicillin-resistant Staphylococcus aureus infections, offering a potential new drug in the fight against this pathogen.
Drug maker Melinta has submitted their new antibiotic Baxdela for review by the US Food and Drug Administration, with the hopes that it will bring a new treatment option for people suffering from methicillin-resistant Staphylococcus aureus (MRSA).
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512